As the CLIA-certified laboratory of the Glioblastoma Foundation, this state-of-the-art facility offers whole-genome methylation testing to uncover the genetic alterations driving each patient’s glioblastoma, such as MGMT methylation status and gene alterations, and supports an accurate diagnosis as the starting point of any treatment plan. The Laboratory empowers clinicians with the critical molecular insights needed to guide personalized therapy decisions and improve outcomes for a disease that has long resisted one-size-fits-all treatments.